Financial Performance - For the six months ended June 30, 2024, the revenue was approximately RMB 652.8 million, an increase of about 2.1% compared to RMB 639.5 million for the same period in 2023[2]. - The gross profit for the same period was approximately RMB 515.4 million, reflecting a growth of about 2.1% from RMB 504.8 million in the previous year[2]. - The net profit attributable to the owners of the company was approximately RMB 205.6 million, a decrease of about 6.6% from RMB 220.2 million in the same period of 2023, primarily due to increased employee costs and reduced foreign exchange gains[2]. - The operating profit for the six months was RMB 202.0 million, down from RMB 255.2 million in the same period last year[4]. - The company reported a basic and diluted earnings per share of RMB 4.6 cents, down from RMB 4.9 cents in the same period last year[4]. - The company reported a pre-tax profit of RMB 208,645 thousand for the six months ended June 30, 2024, down from RMB 256,421 thousand for the same period in 2023[11][12]. - The company’s net profit attributable to shareholders was approximately RMB 205.6 million, a decrease of about RMB 14.6 million or approximately 6.6% compared to RMB 220.2 million in the same period of 2023[39]. - The company’s net profit attributable to shareholders decreased by approximately 8.6% from RMB 255.5 million for the six months ended June 30, 2023, to approximately RMB 233.6 million for the six months ending June 30, 2024[58]. - Excluding non-recurring items, the net profit attributable to shareholders decreased from approximately RMB 220.2 million to approximately RMB 205.6 million, a decline of about 6.6%[58]. Revenue Breakdown - For the six months ended June 30, 2024, total external sales amounted to RMB 652,831 thousand, with structural heart disease business contributing RMB 271,250 thousand, peripheral vascular business RMB 380,725 thousand, and electrophysiology business RMB 856 thousand[11]. - Revenue from the structural heart disease business was approximately RMB 271.2 million, representing an increase of about 11.2% compared to RMB 243.9 million in the same period of 2023[44]. - Revenue from the peripheral vascular business was approximately RMB 380.7 million, an increase of about 5.0% compared to RMB 362.7 million in the same period of 2023[45]. - Revenue from the electrophysiology business significantly decreased by approximately 97.3%, contributing only RMB 0.9 million compared to RMB 32.9 million in the same period of 2023[46]. - Domestic sales decreased by approximately 4.7%, while overseas sales increased by approximately 29.8% compared to the same period in 2023, driven by the company's active overseas expansion and effective marketing strategies[39]. Assets and Liabilities - The total assets as of June 30, 2024, were RMB 2,600.9 million, compared to RMB 2,465.2 million as of December 31, 2023[5]. - The total liabilities for the operating segments as of June 30, 2024, were RMB 322,641 thousand, compared to RMB 317,411 thousand as of December 31, 2023[14]. - The company's cash and cash equivalents decreased to RMB 832.6 million from RMB 979.3 million as of December 31, 2023[5]. - Trade receivables as of June 30, 2024, total RMB 122,173,000, an increase of 16.2% from RMB 105,185,000 as of December 31, 2023[29]. - Other receivables and prepayments amount to RMB 505,394,000 as of June 30, 2024, up from RMB 463,041,000 as of December 31, 2023, reflecting an increase of 9.1%[30]. - Trade payables as of June 30, 2024, are RMB 94,313,000, a decrease of 24.0% from RMB 124,086,000 as of December 31, 2023[33]. - The current liabilities totaled approximately RMB 826.5 million as of June 30, 2024, compared to RMB 770.1 million as of December 31, 2023[61]. - The company's debt-to-asset ratio was approximately 2.9% as of June 30, 2024, compared to zero as of December 31, 2023[64]. Research and Development - The company’s research and development expenses for the six months ended June 30, 2024, totaled RMB 139,926 thousand, compared to RMB 110,607 thousand for the same period in 2023[11][12]. - Research and development expenses increased by approximately 26.5% from about RMB 110.6 million for the six months ended June 30, 2023, to about RMB 139.9 million for the six months ended June 30, 2024[53]. - The company submitted 80 patent applications and successfully obtained 69 patents during the six months ended June 30, 2024, bringing the total to 2,198 effective patent applications, with 1,008 patents granted as of June 30, 2024[42]. Strategic Initiatives - The company has received regulatory approvals for several innovative medical devices, including the DiAcuTM biopsy needle and HeartRTM occluder, enhancing its product portfolio and market competitiveness[41]. - The company is currently in the clinical trial phase for several products, including the X-ClipTM transcatheter mitral valve clip system, which is expected to expand its offerings in the cardiovascular market[41]. - The group aims to identify growth opportunities within the healthcare sector and seeks strategic partnerships to enhance its product line and expand its business scale[66]. - The group is focusing on upgrading its left atrial appendage occluder to meet the growing treatment demand, with expectations of increasing global market share[72]. - The group is optimistic about the market performance of its domestic pacemaker series due to significant unmet demand for pacemaker implantation in China[74]. - The company is actively seeking collaboration and investment opportunities with high-growth potential enterprises in the global healthcare sector[80]. Corporate Governance and Compliance - The company is committed to high standards of corporate governance to protect shareholder interests and enhance corporate value[82]. - The audit committee reviewed the interim results, confirming compliance with relevant accounting standards and regulations[84].
先健科技(01302) - 2024 - 中期业绩